US FDA Exploring Furlough Possibility If User Fee Bill Not Enacted In Time
Executive Summary
Furloughs would allow affected FDA staff to remain employed, while a layoffs would require affected workers to be rehired.
You may also be interested in...
Will US FDA User Fee Deal Allow BsUFA Reg Science Research To Start?
The FDA had picked grantees for the initial round of biosimilar regulatory science research, but told them not to start major activities until the user fee reauthorization was assured. Congress now appears to have reached deal for a ‘practically clean’ reauthorization.
A Pivotal September For US FDA And Commissioner Califf
The month of September will be a crucial time for the US Food & Drug Administration and the legacy of its commissioner, Robert Califf. The agency will be taking several significant regulatory actions – but also crossing its fingers that legislation to assure its funding is secured.
US FDA’s Biosimilars Group Will Conduct Some Supplement Reviews, Become ‘Like Another Discipline’
Office of Therapeutic Biologics and Biosimilars Director Sarah Yim says in an interview with the Pink Sheet that more staff are being added to deal with labeling supplements.